OBJECTIVE: To examine whether the level of primary resistance to HIV drugs is increasing in the United Kingdom. DESIGN: Multicentre observational study. SETTING: All virology laboratories in the United Kingdom carrying out tests for HIV resistance as part of routine clinical care. PARTICIPANTS: 2357 people infected with HIV who were tested for resistance before receiving antiretroviral therapy. MAIN OUTCOME MEASURE: Prevalence of drug resistance on basis of the Stanford genotypic interpretation system. RESULTS: Over the study period (February 1996 to May 2003), 335 (14.2%, 95% confidence interval 12.8% to 15.7%) samples had mutations that conferred resistance to one or more antiretroviral drugs (9.3% high level resistance, 5.9% medium level resistance). The prevalence of primary resistance has increased markedly over time, although patterns are specific to drug class; the largest increase was for non-nucleoside reverse transcriptase inhibitors. In 2002-3, the prevalence of resistance to any antiretroviral drug to nucleoside or nucleotide reverse transcriptase inhibitors, to non-nucleoside reverse transcriptase inhibitors, or to protease inhibitors was 19.2% (15.7% to 23.2%), 12.4% (9.5% to 15.9%), 8.1% (5.8% to 11.1%), and 6.6% (4.4% to 9.3%), respectively. The risk of primary resistance was only weakly related to most demographic and clinical factors, including ethnicity and viral subtype. CONCLUSIONS: The United Kingdom has one of the highest reported rates of primary resistance to HIV drugs worldwide. Prevalence seems still to be increasing and is high in all demographic subgroups.
OBJECTIVE: To examine whether the level of primary resistance to HIV drugs is increasing in the United Kingdom. DESIGN: Multicentre observational study. SETTING: All virology laboratories in the United Kingdom carrying out tests for HIV resistance as part of routine clinical care. PARTICIPANTS: 2357 people infected with HIV who were tested for resistance before receiving antiretroviral therapy. MAIN OUTCOME MEASURE: Prevalence of drug resistance on basis of the Stanford genotypic interpretation system. RESULTS: Over the study period (February 1996 to May 2003), 335 (14.2%, 95% confidence interval 12.8% to 15.7%) samples had mutations that conferred resistance to one or more antiretroviral drugs (9.3% high level resistance, 5.9% medium level resistance). The prevalence of primary resistance has increased markedly over time, although patterns are specific to drug class; the largest increase was for non-nucleoside reverse transcriptase inhibitors. In 2002-3, the prevalence of resistance to any antiretroviral drug to nucleoside or nucleotide reverse transcriptase inhibitors, to non-nucleoside reverse transcriptase inhibitors, or to protease inhibitors was 19.2% (15.7% to 23.2%), 12.4% (9.5% to 15.9%), 8.1% (5.8% to 11.1%), and 6.6% (4.4% to 9.3%), respectively. The risk of primary resistance was only weakly related to most demographic and clinical factors, including ethnicity and viral subtype. CONCLUSIONS: The United Kingdom has one of the highest reported rates of primary resistance to HIV drugs worldwide. Prevalence seems still to be increasing and is high in all demographic subgroups.
Authors: Victoria A Johnson; Francoise Brun-Vézinet; Bonaventura Clotet; Brian Conway; Richard T D'Aquila; Lisa M Demeter; Daniel R Kuritzkes; Deenan Pillay; Jonathan M Schapiro; Amalio Telenti; Douglas D Richman Journal: Top HIV Med Date: 2004 Oct-Nov
Authors: A M Vandamme; A Sönnerborg; M Ait-Khaled; J Albert; B Asjo; L Bacheler; D Banhegyi; C Boucher; F Brun-Vézinet; R Camacho; P Clevenbergh; N Clumeck; N Dedes; A De Luca; H W Doerr; J L Faudon; G Gatti; J Gerstoft; W W Hall; A Hatzakis; N Hellmann; A Horban; J D Lundgren; D Kempf; M Miller; V Miller; T W Myers; C Nielsen; M Opravil; L Palmisano; C F Perno; A Phillips; D Pillay; T Pumarola; L Ruiz; M Salminen; J Schapiro; B Schmidt; J C Schmit; R Schuurman; E Shulse; V Soriano; S Staszewski; S Vella; M Youle; R Ziermann; L Perrin Journal: Antivir Ther Date: 2004-12
Authors: Susan J Little; Sarah Holte; Jean-Pierre Routy; Eric S Daar; Marty Markowitz; Ann C Collier; Richard A Koup; John W Mellors; Elizabeth Connick; Brian Conway; Michael Kilby; Lei Wang; Jeannette M Whitcomb; Nicholas S Hellmann; Douglas D Richman Journal: N Engl J Med Date: 2002-08-08 Impact factor: 91.245
Authors: Robert M Grant; Frederick M Hecht; Maria Warmerdam; Lea Liu; Teri Liegler; Christos J Petropoulos; Nicholas S Hellmann; Margaret Chesney; Michael P Busch; James O Kahn Journal: JAMA Date: 2002-07-10 Impact factor: 56.272
Authors: Catherine V Gale; Richard Myers; Richard S Tedder; Ian G Williams; Paul Kellam Journal: AIDS Res Hum Retroviruses Date: 2004-05 Impact factor: 2.205
Authors: Robert W Shafer; Soo-Yon Rhee; Deenan Pillay; Veronica Miller; Paul Sandstrom; Jonathan M Schapiro; Daniel R Kuritzkes; Diane Bennett Journal: AIDS Date: 2007-01-11 Impact factor: 4.177
Authors: Ivana Grgic; Snjezana Zidovec Lepej; Maja M Lunar; Mario Poljak; Adriana Vince; Ivana Baca Vrakela; Ana Planinic; Katja Seme; Josip Begovac Journal: AIDS Res Hum Retroviruses Date: 2012-10-04 Impact factor: 2.205
Authors: Christopher B Hurt; Sandra I McCoy; Joann Kuruc; Julie Ae Nelson; Melissa Kerkau; Susan Fiscus; Kara McGee; Joseph Sebastian; Peter Leone; Christopher Pilcher; Charles Hicks; Joseph Eron Journal: Antivir Ther Date: 2009
Authors: Larissa A Wenning; Evan J Friedman; James T Kost; Sheila A Breidinger; Jon E Stek; Kenneth C Lasseter; Keith M Gottesdiener; Joshua Chen; Hedy Teppler; John A Wagner; Julie A Stone; Marian Iwamoto Journal: Antimicrob Agents Chemother Date: 2008-07-14 Impact factor: 5.191